Is EVAX or MTVA more profitable?

Evaxion A/S's return on equity of -61.43% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets Evaxion A/S N/A -61.43% -34.23% MetaVia N/A -209.67% -107.91%

Does the media refer more to EVAX or MTVA?

In the previous week, MetaVia had 1 more articles in the media than Evaxion A/S. MarketBeat recorded 5 mentions for MetaVia and 4 mentions for Evaxion A/S. MetaVia's average media sentiment score of 0.75 beat Evaxion A/S's score of 0.45 indicating that MetaVia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evaxion A/S 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MetaVia 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MCRB or MTVA more profitable?

MetaVia has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. Seres Therapeutics' return on equity of -114.82% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets Seres Therapeutics -1,192.94% -114.82% -34.15% MetaVia N/A -209.67% -107.91%

Does the media refer more to MCRB or MTVA?

In the previous week, MetaVia had 3 more articles in the media than Seres Therapeutics. MarketBeat recorded 5 mentions for MetaVia and 2 mentions for Seres Therapeutics. MetaVia's average media sentiment score of 0.75 beat Seres Therapeutics' score of 0.60 indicating that MetaVia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seres Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MetaVia 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend MTVA or BYSI?

MetaVia currently has a consensus price target of $20.00, indicating a potential upside of 1,370.59%. Given MetaVia's stronger consensus rating and higher possible upside, equities analysts clearly believe MetaVia is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MetaVia 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, MTVA or BYSI?

BeyondSpring is trading at a lower price-to-earnings ratio than MetaVia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MetaVia N/A N/A -$12.97M -$3.23 N/A BeyondSpring N/A N/A -$1.01M -$0.12 N/A

Is MTVA or BYSI more profitable?

BeyondSpring's return on equity of 0.00% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets MetaVia N/A -209.67% -107.91% BeyondSpring N/A N/A -28.88%

Does the media favor MTVA or BYSI?

In the previous week, MetaVia had 3 more articles in the media than BeyondSpring. MarketBeat recorded 5 mentions for MetaVia and 2 mentions for BeyondSpring. MetaVia's average media sentiment score of 0.75 beat BeyondSpring's score of 0.61 indicating that MetaVia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MetaVia 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeyondSpring 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ATYR or MTVA?

MetaVia has a consensus target price of $20.00, indicating a potential upside of 1,370.59%. Given MetaVia's higher possible upside, analysts plainly believe MetaVia is more favorable than aTyr Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 MetaVia 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ATYR or MTVA more profitable?

aTyr Pharma's return on equity of -95.89% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets aTyr Pharma N/A -95.89% -69.67% MetaVia N/A -209.67% -107.91%

Does the media prefer ATYR or MTVA?

In the previous week, MetaVia had 1 more articles in the media than aTyr Pharma. MarketBeat recorded 5 mentions for MetaVia and 4 mentions for aTyr Pharma. MetaVia's average media sentiment score of 0.75 beat aTyr Pharma's score of 0.41 indicating that MetaVia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment aTyr Pharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MetaVia 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, KYNB or MTVA?

Kyntra Bio has higher revenue and earnings than MetaVia. MetaVia is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kyntra Bio $6.44M 3.50 $183.45M $45.30 0.12 MetaVia N/A N/A -$12.97M -$3.23 N/A

Is KYNB or MTVA more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to MetaVia's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets Kyntra Bio 2,199.13% N/A -47.27% MetaVia N/A -209.67% -107.91%

Does the media refer more to KYNB or MTVA?

In the previous week, Kyntra Bio and Kyntra Bio both had 5 articles in the media. MetaVia's average media sentiment score of 0.75 beat Kyntra Bio's score of 0.16 indicating that MetaVia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MetaVia 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MetaVia (MTVA) Competitors

$1.36 -0.07 (-4.90%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$1.30 -0.06 (-4.04%)

As of 05:44 AM Eastern

Compare

MTVA vs. EVAX, MCRB, BYSI, ATYR, and KYNB

Should you buy MetaVia stock or one of its competitors? MetaVia's main competitors and comparable companies include Evaxion A/S (EVAX), Seres Therapeutics (MCRB), BeyondSpring (BYSI), aTyr Pharma (ATYR), and Kyntra Bio (KYNB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MetaVia compare to Evaxion A/S?

Evaxion A/S (NASDAQ:EVAX) and MetaVia (NASDAQ:MTVA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

11.0% of Evaxion A/S shares are owned by institutional investors. Comparatively, 1.4% of MetaVia shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by insiders. Comparatively, 0.6% of MetaVia shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Evaxion A/S currently has a consensus target price of $11.00, suggesting a potential upside of 292.86%. MetaVia has a consensus target price of $20.00, suggesting a potential upside of 1,370.59%. Given MetaVia's higher probable upside, analysts clearly believe MetaVia is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Evaxion A/S has higher revenue and earnings than MetaVia. Evaxion A/S is trading at a lower price-to-earnings ratio than MetaVia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	3.35	-$7.71M	-$1.21	N/A
MetaVia	N/A	N/A	-$12.97M	-$3.23	N/A

Evaxion A/S has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, MetaVia has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

Evaxion A/S's return on equity of -61.43% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-61.43%	-34.23%
MetaVia	N/A	-209.67%	-107.91%

In the previous week, MetaVia had 1 more articles in the media than Evaxion A/S. MarketBeat recorded 5 mentions for MetaVia and 4 mentions for Evaxion A/S. MetaVia's average media sentiment score of 0.75 beat Evaxion A/S's score of 0.45 indicating that MetaVia is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evaxion A/S	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MetaVia	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Evaxion A/S beats MetaVia on 9 of the 13 factors compared between the two stocks.

How does MetaVia compare to Seres Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and MetaVia (NASDAQ:MTVA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

Seres Therapeutics currently has a consensus price target of $17.00, suggesting a potential upside of 602.48%. MetaVia has a consensus price target of $20.00, suggesting a potential upside of 1,370.59%. Given MetaVia's higher possible upside, analysts plainly believe MetaVia is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Seres Therapeutics has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, MetaVia has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

In the previous week, MetaVia had 3 more articles in the media than Seres Therapeutics. MarketBeat recorded 5 mentions for MetaVia and 2 mentions for Seres Therapeutics. MetaVia's average media sentiment score of 0.75 beat Seres Therapeutics' score of 0.60 indicating that MetaVia is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seres Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MetaVia	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MetaVia has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. Seres Therapeutics' return on equity of -114.82% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%
MetaVia	N/A	-209.67%	-107.91%

59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 1.4% of MetaVia shares are held by institutional investors. 5.2% of Seres Therapeutics shares are held by company insiders. Comparatively, 0.6% of MetaVia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Seres Therapeutics has higher revenue and earnings than MetaVia. Seres Therapeutics is trading at a lower price-to-earnings ratio than MetaVia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	30.79	$5.70M	-$2.43	N/A
MetaVia	N/A	N/A	-$12.97M	-$3.23	N/A

Summary

Seres Therapeutics beats MetaVia on 9 of the 14 factors compared between the two stocks.

How does MetaVia compare to BeyondSpring?

MetaVia (NASDAQ:MTVA) and BeyondSpring (NASDAQ:BYSI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

1.4% of MetaVia shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 0.6% of MetaVia shares are owned by insiders. Comparatively, 29.3% of BeyondSpring shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

BeyondSpring is trading at a lower price-to-earnings ratio than MetaVia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MetaVia	N/A	N/A	-$12.97M	-$3.23	N/A
BeyondSpring	N/A	N/A	-$1.01M	-$0.12	N/A

BeyondSpring's return on equity of 0.00% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-209.67%	-107.91%
BeyondSpring	N/A	N/A	-28.88%

In the previous week, MetaVia had 3 more articles in the media than BeyondSpring. MarketBeat recorded 5 mentions for MetaVia and 2 mentions for BeyondSpring. MetaVia's average media sentiment score of 0.75 beat BeyondSpring's score of 0.61 indicating that MetaVia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MetaVia	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeyondSpring	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MetaVia currently has a consensus price target of $20.00, indicating a potential upside of 1,370.59%. Given MetaVia's stronger consensus rating and higher possible upside, equities analysts clearly believe MetaVia is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

MetaVia has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, BeyondSpring has a beta of -0.21, suggesting that its share price is 121% less volatile than the broader market.

Summary

MetaVia and BeyondSpring tied by winning 6 of the 12 factors compared between the two stocks.

How does MetaVia compare to aTyr Pharma?

aTyr Pharma (NASDAQ:ATYR) and MetaVia (NASDAQ:MTVA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

In the previous week, MetaVia had 1 more articles in the media than aTyr Pharma. MarketBeat recorded 5 mentions for MetaVia and 4 mentions for aTyr Pharma. MetaVia's average media sentiment score of 0.75 beat aTyr Pharma's score of 0.41 indicating that MetaVia is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
aTyr Pharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MetaVia	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

aTyr Pharma's return on equity of -95.89% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-95.89%	-69.67%
MetaVia	N/A	-209.67%	-107.91%

MetaVia has lower revenue, but higher earnings than aTyr Pharma. MetaVia is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	94.63	-$74.12M	-$0.62	N/A
MetaVia	N/A	N/A	-$12.97M	-$3.23	N/A

aTyr Pharma has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, MetaVia has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

MetaVia has a consensus target price of $20.00, indicating a potential upside of 1,370.59%. Given MetaVia's higher possible upside, analysts plainly believe MetaVia is more favorable than aTyr Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 1.4% of MetaVia shares are owned by institutional investors. 5.0% of aTyr Pharma shares are owned by insiders. Comparatively, 0.6% of MetaVia shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

aTyr Pharma beats MetaVia on 8 of the 13 factors compared between the two stocks.

How does MetaVia compare to Kyntra Bio?

Kyntra Bio (NASDAQ:KYNB) and MetaVia (NASDAQ:MTVA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Kyntra Bio has higher revenue and earnings than MetaVia. MetaVia is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	3.50	$183.45M	$45.30	0.12
MetaVia	N/A	N/A	-$12.97M	-$3.23	N/A

72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 1.4% of MetaVia shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by company insiders. Comparatively, 0.6% of MetaVia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Kyntra Bio currently has a consensus price target of $36.80, indicating a potential upside of 560.68%. MetaVia has a consensus price target of $20.00, indicating a potential upside of 1,370.59%. Given MetaVia's higher probable upside, analysts plainly believe MetaVia is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Kyntra Bio has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, MetaVia has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

In the previous week, Kyntra Bio and Kyntra Bio both had 5 articles in the media. MetaVia's average media sentiment score of 0.75 beat Kyntra Bio's score of 0.16 indicating that MetaVia is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MetaVia	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kyntra Bio has a net margin of 2,199.13% compared to MetaVia's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-47.27%
MetaVia	N/A	-209.67%	-107.91%

Summary

Kyntra Bio beats MetaVia on 11 of the 13 factors compared between the two stocks.

Get MetaVia News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MTVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MTVA vs. The Competition

Export

Metric	MetaVia	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.39M	$3.84B	$7.18B	$13.18B
Dividend Yield	N/A	3.65%	2.52%	19.59%
P/E Ratio	N/A	10.30	215.33	19.57
Price / Sales	N/A	1,163.44	571.63	81.29
Price / Cash	N/A	119.79	76.68	52.75
Price / Book	0.59	16.17	10.37	5.92
Net Income	-$12.97M	-$22.69M	$3.50B	$380.90M
7 Day Performance	1.49%	-5.80%	-3.49%	-3.90%
1 Month Performance	-13.92%	-12.85%	-7.76%	-6.42%
1 Year Performance	-88.66%	3.02%	0.82%	-6.01%

MetaVia Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MTVA MetaVia	2.6954 of 5 stars	$1.36 -4.9%	$20.00 +1,370.6%	-87.9%	$7.39M	N/A	N/A	8	Short Interest Decrease
EVAX Evaxion A/S	2.8143 of 5 stars	$3.02 -4.4%	$11.00 +264.2%	-64.3%	$27.24M	$7.53M	N/A	46
MCRB Seres Therapeutics	2.528 of 5 stars	$2.62 -3.7%	$17.00 +549.1%	-87.7%	$26.28M	$790K	N/A	66	Gap Up High Trading Volume
BYSI BeyondSpring	0.315 of 5 stars	$0.64 -1.5%	N/A	-64.2%	$26.15M	$1.75M	N/A	44
ATYR aTyr Pharma	0.7912 of 5 stars	$0.25 -9.1%	N/A	-82.4%	$24.82M	$190K	N/A	58

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MTVA) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MetaVia (MTVA) Competitors